Breaking News
November 22, 2018 - Response to daily stressors plays important role in cognitive health of older adults
November 22, 2018 - Efficient method for producing induced pluripotent stem cells
November 22, 2018 - Report outlines inequalities in access to healthcare
November 22, 2018 - New research center will pave way to better diagnosis and treatment of skin diseases
November 22, 2018 - Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient
November 22, 2018 - Lung Cancer Tumor Markers: MedlinePlus Lab Test Information
November 22, 2018 - Patchy distribution of joint inflammation resolved
November 22, 2018 - Researchers find crucial inhibitory role for signal peptide in GluK1 trafficking
November 22, 2018 - nutritional supplement, could slow some cancers
November 22, 2018 - Researchers awarded $7 million funding in Pancreatic Cancer Collective’s ‘New Therapies Challenge’
November 22, 2018 - UMN researchers focus on improving dermatologic care for sexual and gender minority patients
November 22, 2018 - Researchers harness visible light to develop safer building block for drug discovery
November 22, 2018 - Scientists identify key protein involved in Hantavirus Pulmonary Syndrome
November 22, 2018 - ACAAI: Oral Immunotherapy Is Protective in Peanut Allergy
November 22, 2018 - Arthritis and depression often occur together in older adults
November 22, 2018 - Scientists uncover unexpected ‘foreign’ genes in tiny itch-inducing chigger mite
November 22, 2018 - Negative social cues on tobacco packaging could help reduce smoking intentions
November 22, 2018 - Study finds no differences in quit rates for ‘dual users’ of both traditional and electronic cigarettes
November 22, 2018 - Immunity connects gut microbiota and age-related pathologies
November 22, 2018 - New diagnostics based on nanopore analytics and AI can identify single influenza virions
November 22, 2018 - Blocking activity of plasma protein can be possible way to protect against radiation-induced injury
November 22, 2018 - Secondhand Pot Smoke Found in Kids’ Lungs
November 22, 2018 - Air pollution may be linked to heightened dementia risk
November 22, 2018 - Brain implant lets people with limb paralysis compose and send emails, select videos and even play music, just by thinking
November 22, 2018 - Should health-care workers press charges against violent patients?
November 22, 2018 - Obesity linked to COPD in never-smokers
November 22, 2018 - Improving dementia treatment and staff training in care homes saves thousands of pounds per year
November 22, 2018 - Researchers identify genetic changes that could increase risk for death by suicide
November 22, 2018 - John Snow Labs launches new Data Market to help healthcare and life science innovators
November 22, 2018 - New inhibitor could hold key to treating Acute Respiratory Distress Syndrome
November 22, 2018 - Misconceptions about opioid use undermine pain control among Asian cancer patients
November 22, 2018 - Owlstone Medical named Medtech Company of the Year
November 22, 2018 - Anabolic steroids may increase risk of early death in men
November 22, 2018 - Researchers develop model that predicts transmissibility of viral zoonoses
November 22, 2018 - Evidence mounts that an eye scan may detect early Alzheimer’s disease
November 22, 2018 - Sensors could provide dexterity to robots, with potential surgical applications
November 22, 2018 - Why Are We Still So Fat?
November 22, 2018 - MRI scans may help predict dementia risk
November 22, 2018 - Groundbreaking research projects show how AI can be used to predict under diagnosed chronic diseases
November 21, 2018 - Stand Up to Cancer supports potential approach to more efficiently target pancreatic cancer
November 21, 2018 - Using smartphone confocal microscopes to stop cancer
November 21, 2018 - Self-care program for COPD patients reduces emergency room visits and burdensome symptoms
November 21, 2018 - Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
November 21, 2018 - Cocaine adulterant may cause brain damage
November 21, 2018 - Amid the devastation, a Stanford doctor stitches up George, a search dog
November 21, 2018 - America’s Health-Care System Is Making the Opioid Crisis Worse
November 21, 2018 - Colorectal cancer screening reduces need for intense treatments among male patients
November 21, 2018 - Scientists find evidence of prions in the eyes of CJD patients
November 21, 2018 - Study explores individual and organizational risk factors for one-year mortality in ICU survivors
November 21, 2018 - Pulmonologists want more information on inhalation devices for COPD
November 21, 2018 - Cessation fatigue predicts relapse rate after attempts to quit smoking
November 21, 2018 - Special care should be taken with drugs that inhibit epigenetic factors, study suggests
November 21, 2018 - More than one in ten heavy cannabis users experience withdrawal after quitting cannabis
November 21, 2018 - Reflections on the California fires
November 21, 2018 - Donna Lynne Appointed to Key Leadership Role at CUIMC
November 21, 2018 - Smoke-free laws associated with reduced systolic blood pressure
November 21, 2018 - Achieving new guideline blood pressure goals may prevent 3 million cardiovascular events
November 21, 2018 - LDR brachytherapy for treating early-stage prostate cancer lacks conclusive data
November 21, 2018 - Older adults with CVD more likely to experience rapid functional decline
November 21, 2018 - Purified omega-3 and aspirin reduce pre-cancerous bowel polyps, shows study
November 21, 2018 - Study warns that potential epigenetic therapy may boost lung cancer stem cells
November 21, 2018 - Noise pollution in hospital impact quality and safety of healthcare
November 21, 2018 - Interventions to improve sleep may reduce risk of falls
November 21, 2018 - Outdoor air pollution linked to intellectual disabilities in children
November 21, 2018 - Study highlights need for better screening tools to detect maternal sepsis
November 21, 2018 - Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM
November 21, 2018 - Researchers stop ‘sneaky’ cancer cells in their tracks
November 21, 2018 - People who are afraid to draw their blood over-estimate the risk of fainting
November 21, 2018 - Personalized physical exercise reverses functional, cognitive deterioration in the elderly
November 21, 2018 - COPD linked to obesity in older women who have never smoked
November 21, 2018 - AHA: Cold-Weather Drinks Are Here, But Watch Out for the Calories
November 21, 2018 - Crowds line up at 1st East Coast pot shops
November 21, 2018 - Merck declares 2018 Life Science Award winners
November 21, 2018 - Many people underestimate the impact of sprains, say foot scientists
November 21, 2018 - Lower levels of protein make squamous carcinoma cells more invasive
November 21, 2018 - Study highlights a new predictor of type 2 diabetes
November 21, 2018 - NTU and TTSH join forces to improve doctor-patient communication
November 21, 2018 - New low-cost injectable hydrogel could help wounds heal faster
November 21, 2018 - Merck Announces Winners of 2018 Life Science Awards
November 21, 2018 - Check your medical records for dangerous errors
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

image_pdfDownload PDFimage_print

Treatment for Dry Eye Disease

Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 16, 2018– Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease.

There are an estimated 33 million patients with dry eye disease in the U.S. and Kala’s market research indicates that approximately 90% of these patients have flares associated with their dry eye disease. If approved, KPI-121 0.25% could offer a favorable management option for these dry eye flares and other dry eye-associated conditions.

KPI-121 0.25% utilizes Kala’s AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, which are selectively-sized nanoparticles with proprietary coatings that significantly enhance drug penetration and distribution in ocular tissues. In preclinical studies, MPPs increased drug delivery into ocular tissues more than three-fold by facilitating penetration through the tear film mucus.

The NDA filing is supported by three clinical trials studying approximately 2,000 patients with dry eye disease, including one Phase 2 trial and two Phase 3 efficacy and safety trials, STRIDE 1 and STRIDE 2 (STRIDE – Short Term Relief In Dry Eye). KPI-121 0.25% achieved statistical significance for the primary sign endpoint of conjunctival hyperemia in the intent to treat (ITT) population in the Phase 2 trial and both Phase 3 trials. KPI-121 0.25% also achieved statistical significance for the primary symptom endpoint of ocular discomfort severity at Day 15 in the ITT population in STRIDE 1 with a trend towards a treatment effect in STRIDE 2, as well as a positive treatment effect observed in Phase 2. Statistical significance was achieved in STRIDE 1 for the second primary symptom endpoint of ocular discomfort severity at Day 15 in patients with a more severe baseline discomfort, with a strong trend towards a treatment effect observed for the same endpoint in STRIDE 2. Positive treatment effects were also observed in both trials for the symptom endpoint of ocular discomfort severity in the ITT population at Day 8, which was a key pre-specified secondary endpoint. KPI-121 0.25% was well-tolerated in all three trials with elevation in intra-ocular pressure, a known side effect with topical corticosteroids, similar to vehicle (placebo).

“We are pleased to submit the NDA for KPI-121 0.25% to the FDA,” said Kim Brazzell, Ph.D., Chief Medical Officer of Kala Pharmaceuticals. “We believe the data from STRIDE 1, STRIDE 2 and the Phase 2 trials demonstrate a robust data package supporting the clinically meaningful efficacy, safety and tolerability of KPI-121 0.25%. Today, there are limited treatment options for dry eye disease and KPI-121 0.25% has the opportunity to address significant unmet needs for patients and health care professionals.”

Kala has also initiated a third Phase 3 clinical trial, STRIDE 3, evaluating KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The primary endpoints for the study will be symptom-focused. Kala has conducted a comprehensive analysis of the data generated in the previous three clinical trials and believes it has identified key factors that contributed to the differences observed in the results from STRIDE 2 compared to those of STRIDE 1 and Phase 2. Kala has integrated these factors into the trial design of STRIDE 3, which it believes will improve the probability of success for the trial. The Company expects to report top-line results for STRIDE 3 in the fourth quarter of 2019.

About STRIDE 3 Phase 3 Trial Design

The STRIDE 3 trial is a multicenter, randomized, double-blind, placebo controlled, parallel-arm study comparing KPI-121 0.25% to placebo, each dosed four times a day (QID) for 14 days, in approximately 900 patients with dry eye disease. Subjects who meet initial screening and inclusion/exclusion criteria undergo a 2-week run-in period with placebo. Subjects who continue to meet inclusion/exclusion criteria after the run-in are randomized to either KPI-121 0.25% or placebo. The primary endpoints, Day 15 ocular discomfort severity in the ITT population and Day 15 ocular discomfort severity in patients with a more severe baseline discomfort, are based upon a patient diary in which ocular discomfort is recorded daily over the entire course of the trial using a visual analog grading scale. Topline data from this study is expected in the fourth quarter of 2019.

About KPI-121 0.25%

Kala is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease utilizing a two-week course of therapy administered four times a day. Dry eye disease is a chronic, episodic, multifactorial disease affecting the tears and ocular surface and can involve tear film instability, inflammation, discomfort, visual disturbance and ocular surface damage. KPI-121 0.25% utilizes Kala’s AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology to enhance penetration of loteprednol etabonate (LE) into target tissue of the eye. In preclinical studies, the AMPPLIFY Drug Delivery Technology increased delivery of loteprednol etabonate (LE) into ocular tissues more than three-fold compared to current LE products by facilitating penetration through the tear film mucus. Kala has completed one Phase 2 and two Phase 3 clinical trials of KPI-121 0.25%. Kala believes that KPI-121 0.25%’s broad mechanism of action, rapid onset of relief of both signs and symptoms, favorable tolerability and safety profile and the potential to be complementary to existing therapies, could result in a favorable profile for the management of dry eye flares and other dry eye associated conditions.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, LE, designed for ocular applications, resulting in recently approved INVELTYS for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding the Company’s lead product candidate, KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease, KPI-121 0.25% potentially being the first FDA-approved product for the treatment of dry eye flares, KPI-121 0.25% having the opportunity to address significant unmet needs for patients and health care professionals, and the Company’s expectation to report top-line results for STRIDE 3 in the fourth quarter of 2019. All statements, other than statements of historical facts, contained in this Press Release, including statements regarding the Company’s strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of various risks and uncertainties, including but not limited to: whether the Company will be able to successfully implement its commercialization plans for INVELTYS; whether the market opportunity for INVELTYS is consistent with the Company’s expectations and market research; data from the Company’s Phase 3 clinical trials of KPI-121 0.25% will warrant filing of the NDA; whether any additional clinical trials will be initiated or required for KPI-121 0.25% prior to submission or filing of an NDA, or at all, and whether any such NDA will be accepted for filing and/or approved; the Company’s ability to build a specialty sales force and prepare for commercial launch of INVELTYS on the timeline expected, or at all; whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements for the Company’s expected timeline; other matters that could affect the availability or commercial potential of INVELTYS and the Company’s product candidates, including KPI-121 0.25%; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, discussed in the “Risk Factors” section of the Company’s most recently filed Quarterly Report on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission. These forward-looking statements represent the Company’s views as of the date of this release and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Source: Kala Pharmaceuticals, Inc.

Posted: October 2018

KPI-121 0.25% (loteprednol etabonate) FDA Approval History

Tagged with:

About author

Related Articles